Company Overview and News
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819
KUALA LUMPUR (Oct 16): The FBM KLCI reversed its earlier losses and climbed at mid-morning, tracking the modest rise at the regional markets.
UPBMF 5220 7113 5681 TPGVF BATS 4162 2291 2089 5014 7066 0131 6033 7123 5199 TGLVY 4588 PNADF 0026 MYPRY HIPEF PNAGF GEBHF
KUALA LUMPUR: JF Apex Research expects Ideal United Bintang International Bhd, Aturmaju Resources Bhd , Diversified Gateway Solutions Bhd and Diversified Gateway Solutions Bhd to be among the stocks to watch.
KUALA LUMPUR (Oct 16): The FBM KLCI is expected to start on a lacklustre note today, in line with the overnight fall at most global markets, as sentiment at the world bourses remains jittery with rising geopolitical tensions amid the simmering US-Sino trade conflict.
7181 6025 7121 0131
KUALA LUMPUR (Oct 15): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Oct 16) may include Ideal United Bintang International Bhd, Hovid Bhd, Aturmaju Resources Bhd, KiP REIT, Berjaya Media Bhd, Xian Leng Holdings Bhd, Diversified Gateway Solutions Bhd and DBE Gurney Resources Bhd
7181 9687 6025 7121 0131
KUALA LUMPUR (Oct 15): Diversified Gateway Solutions Bhd (DGSB) is proposing a share capital reduction exercise to wipe out its accumulated losses.
KUALA LUMPUR (Oct 8): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 9) may include: UEM Sunrise Bhd, T7 Global Bhd, Reach Energy Bhd, MMC Corp Bhd, Gamuda Bhd, MCE Holdings Bhd and IHH Healthcare Bhd.
5148 5225 7245 Q0F IHHHF 5256 0131 5001
KUALA LUMPUR (Oct 8): Pahang Crown Princess Tengku Datuk Aishah Ahmad Shah has been appointed as the non-executive chairman of Diversified Gateway Solutions Bhd.
7245 0131 5001
KUALA LUMPUR (Sep 5): Diversified Gateway Solutions Bhd’s chairman Datuk Mah Siew Kwok has retired from his position, the group said in a filing today.
KUALA LUMPUR (Aug 20): Omesti Bhd has disposed of a 7.38% stake in Diversified Gateway Solutions Bhd (DGSB) to Insas Bhd for RM6.93 million or 6.3 sen per share via direct business transactions, to pare down its share margin loans and for working capital.
BSMAF 0131 1818
KUALA LUMPUR (Aug 17): Some 110 million shares representing a 7.38% stake in Diversified Gateway Solutions Bhd (DGSB) were traded off-market today.
KUALA LUMPUR (Aug 10): The FBM KLCI pared some of its gains at midday today as decliners overtook advancers, tracking the sentiment at most regional markets.
SPMXF UPBMF 7036 5681 BATS 4162 7765 5015 2089 5014 0131 6033 2593 2852 0143 5029 PNADF SPMXY 3883 0026 MYPRY PNAGF GEBHF
KUALA LUMPUR (July 19): The FBM KLCI pared some its gains at the midday break today and was up 0.44%, against the backdrop of higher regional markets.
PBLOF MLYBY MLYNF 7113 TPGVF 1295 3794 5014 9334 0131 TGLVY 1155 4588 3867 8613 6459 5819 MYPRY 1929
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...